![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Effect of tirzepatide in SURMOUNT-1](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
surmount 1 tirzepatide
Shipping Estimate
surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Effect of tirzepatide in SURMOUNT-1
USD27.78
USD71.78
Pay in 4 interest-free payments of $6.95 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Effect of tirzepatide in SURMOUNT-1](https://www.researchgate.net/profile/Sandeep-Garg-6/publication/379697757/figure/fig1/AS:11431281235310767@1712744795200/Effect-of-tirzepatide-in-SURMOUNT-1-trial-BMI-body-mass-index-CI-confidence-interval_Q320.jpg)
![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Effect of tirzepatide in SURMOUNT-1](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12325-026-03523-5/MediaObjects/12325_2026_3523_Fig1_HTML.png)
![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Effect of tirzepatide in SURMOUNT-1](https://dom-pubs.onlinelibrary.wiley.com/cms/asset/255fe113-017e-4c28-816f-13c8c2e8641f/dom16176-fig-0004-m.jpg)
![surmount 1 tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Effect of tirzepatide in SURMOUNT-1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832c/12326891/91371dd0ccec/DOM-27-5064-g001.jpg)
/assets/images/provider/photos/2737315.jpg)
